- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Lilly, DICE Therapeutics Agree to $2.4B Acquisition Deal
Pharma giant to absorb oral treatment specialist.
Eli Lilly and Company has officially announced a deal to acquire DICE Therapeutics, a biopharma organization focused on the creation of novel oral therapeutic candidates to treat chronic diseases in immunology. Approved by the boards of directors for both companies, Lilly is expected to obtain DICE for approximately $2.4 billion.
"In combination with its novel technology and expertise in drug discovery, DICE's talented workforce and passion for innovation will enhance our efforts to make life better for people living with devastating autoimmune diseases," said Patrik Jonsson, EVP, president of Lilly immunology and Lilly USA, chief customer officer. "We welcome DICE colleagues to Lilly and, together, we can tackle the challenges ahead in finding new treatments for patients with significant unmet medical needs."
Reference: Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology. PR Newswire. June 20, 2023. Accessed June 21, 2023. https://www.prnewswire.com/news-releases/lilly-to-acquire-dice-therapeutics-to-advance-innovation-in-immunology-301854537.html
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
Trends in Continuing Medical Education
April 12th 2024Elliott Yoo, Senior Media Strategist at epocrates, takes a closer look at the trends in CME consumption and what the future of medical education will be – from the priorities for physicians as they juggle learning with patient care, to what type of activities resonate most with prescribers.
